Literature DB >> 8408939

Continuous veno-venous haemofiltration following cardio-pulmonary bypass. Indications and outcome in 35 patients.

S V Baudouin1, J Wiggins, B F Keogh, C J Morgan, T W Evans.   

Abstract

OBJECTIVE: To study the impact of continuous veno-venous haemofiltration on survival in patients with acute renal failure (ARF) following cardio-pulmonary bypass (CPB) surgery.
DESIGN: A retrospective study of all patients requiring haemofiltration after CPB over a 2 year period.
SETTING: A 20 bedded, adult cardothoracic intensive care unit in a postgraduate teaching hospital. PATIENTS: 35 patients (26 male, age range 24-74 years) required haemofiltration (2.7% of the total number of patients undergoing CPB). MAIN
RESULTS: Cardiovascular failure post CPB was the commonest causes of ARF (n = 16). Indications for haemofiltration were uremia (21), oligo-anuria (11), volume overload (2) and hyperkalaemia (1). Mean time from CPB to the initiation of haemofiltration was 8 days (range 0-15 days). Mean urea was 30 mmol/l and creatinine 362 mumol/l immediately prior to treatment. Urea was well-controlled in all patients, although 2 needed haemodiafiltration. Twenty-six patients died during their admission to the ICU (74% mortality). A further 3 patients died during their hospital admission, following discharge from ICU. Outcome was particularly poor in patients with cardiovascular failure following CPB (16 cases, 0 survivors). Survivors tended to commence filtration earlier (mean of 4 vs 7 days for non-survivors) and required treatment for a mean period of 8 days (range 1-26 days). Survival was determined by the number of failed organ systems at the start of haemofiltration. Thus, 100% of patients with single system failure survived, compared to only 10% with 3 or more system failure.
CONCLUSIONS: Despite the theoretical advantages of haemofiltration and the effective control of uraemia the mortality associated with ARF following CPB remains high and is probably determined by the number of failed organs systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408939     DOI: 10.1007/bf01690550

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  18 in total

1.  Septic shock and multiple organ failure: treatment with haemofiltration?

Authors:  A B Groeneveld
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  Renal failure after open heart surgery.

Authors:  J G Bhat; M C Gluck; J Lowenstein; D S Baldwin
Journal:  Ann Intern Med       Date:  1976-06       Impact factor: 25.391

Review 3.  Hemodynamically mediated acute renal failure.

Authors:  B D Myers; S M Moran
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

4.  Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure.

Authors:  M Storck; W H Hartl; E Zimmerer; D Inthorn
Journal:  Lancet       Date:  1991-02-23       Impact factor: 79.321

5.  Prognosis in acute organ-system failure.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Ann Surg       Date:  1985-12       Impact factor: 12.969

6.  Continuous high volume venous-venous haemofiltration in acute renal failure.

Authors:  J Wendon; M Smithies; M Sheppard; K Bullen; J Tinker; D Bihari
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

7.  Acute renal failure and open heart surgery.

Authors:  E D Yeboah; A Petrie; J L Pead
Journal:  Br Med J       Date:  1972-02-12

8.  Acute renal failure following cardiac operations.

Authors:  P Gailiunas; R Chawla; J M Lazarus; L Cohn; J Sanders; J P Merrill
Journal:  J Thorac Cardiovasc Surg       Date:  1980-02       Impact factor: 5.209

9.  Acute renal failure following cardiac surgery.

Authors:  M Hilberman; B D Myers; B J Carrie; G Derby; R L Jamison; E B Stinson
Journal:  J Thorac Cardiovasc Surg       Date:  1979-06       Impact factor: 5.209

Review 10.  Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view.

Authors:  M Schetz; P M Lauwers; P Ferdinande
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

View more
  7 in total

1.  Safety of perioperative hemodialysis and continuous hemodiafiltration for dialysis patients with cardiac surgery.

Authors:  Keiji Kamohara; Masaru Yoshikai; Junji Yunoki; Hideyuki Fumoto; Junichi Murayama; Masakatsu Hamada; Tsuyoshi Itoh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-02

2.  Continuous veno-venous hemofiltration and mortality after cardiac surgery.

Authors:  B Levy; J P Villemot
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

3.  Epidemiology of acute renal failure and outcome of haemodiafiltration in intensive care.

Authors:  B Schwilk; H Wiedeck; B Stein; H Reinelt; H Treiber; U Bothner
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

4.  Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery.

Authors:  Chih-Chung Shiao; Vin-Cent Wu; Wen-Yi Li; Yu-Feng Lin; Fu-Chang Hu; Guang-Huar Young; Chin-Chi Kuo; Tze-Wah Kao; Down-Ming Huang; Yung-Ming Chen; Pi-Ru Tsai; Shuei-Liong Lin; Nai-Kuan Chou; Tzu-Hsin Lin; Yu-Chang Yeh; Chih-Hsien Wang; Anne Chou; Wen-Je Ko; Kwan-Dun Wu
Journal:  Crit Care       Date:  2009-10-30       Impact factor: 9.097

5.  Acute renal replacement therapy in pediatrics.

Authors:  Rajit K Basu; Derek S Wheeler; Stuart Goldstein; Lesley Doughty
Journal:  Int J Nephrol       Date:  2011-06-01

6.  Use of a simply modified drainage catheter for peritoneal dialysis treatment of acute renal failure associated with cardiac surgery in infants.

Authors:  Qiang Chen; Hua Cao; Yun-Nan Hu; Liang-Wan Chen; Jia-Jun He
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

Review 7.  Acute Kidney Injury following Cardiopulmonary Bypass: A Challenging Picture.

Authors:  Dianxiao Liu; Baohui Liu; Zhenxing Liang; Zhi Yang; Fangjian Ma; Yang Yang; Wei Hu
Journal:  Oxid Med Cell Longev       Date:  2021-03-09       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.